SCHEMBL5075649

SCHEMBL5075649

O=CNC1(Cc2cc3c(cc2Cl)OCO3)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.36
CYP3A4 P08684 4/20 0.36
CYP2C19 P33261 4/20 0.36
CYP2D6 P10635 3/20 0.36
CYP2C9 P11712 2/20 0.36
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34
OPRM1 P35372 3/20 0.34
OPRD1 P41143 3/20 0.34
OPRK1 P41145 3/20 0.34
SIGMAR1 Q99720 2/20 0.34
DRD3 P35462 2/20 0.34
OPRL1 P41146 2/20 0.34
CACNA1F O60840 1/20 0.34
CACNA1D Q01668 1/20 0.34
CACNA1S Q13698 1/20 0.34
CACNA1C Q13936 1/20 0.34
DRD1 P21728 1/20 0.34
DRD4 P21917 1/20 0.34
ADRA1D P25100 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5073528 0.72 NPC1 (0.42) CYP3A4CYP2C19CYP2D6CYP2C9KMT2A
SCHEMBL2469029 0.71 CRHBP (0.41) CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9
SCHEMBL27364514 0.71 ALDH1A1 (0.40) CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9
SCHEMBL2467071 0.69 CYP1A2 (0.39) CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9
SCHEMBL24890641 0.68 CRHBP (0.38) CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9
SCHEMBL12404328 0.68 CRHBP (0.43) CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9
SCHEMBL895213 0.67 HPGD (0.55) MAPTKMT2ANPSR1MEN1ALDH1A1
SCHEMBL1041822 0.66 CRHBP (0.44) CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9
SCHEMBL7469245 0.65 SLC22A12 (0.44) CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9
Hydrochloric Acid SCHEMBL11013920 0.64 CRHBP (0.43) CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312242-A1 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES ACTELION PHARMACEUTICALS, LTD. (CH) 2008-12-18 US disclosed
US-7427613-B2 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases ACTELION PHARMACEUTICALS LTD. (CH) 2008-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312242-A1 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES REN, AGTR1, ACE CYP1A2 95/4885CYP3A4 171/4885CYP2C19 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.